Earnings Call · Q1 FY2026·2026-05-11

Q1 26EPS -43.08%·Rev n/aQ4 25EPS -3.98%·Rev n/aQ3 25EPS -26.42%·Rev n/aQ2 25EPS +7.41%·Rev n/a⚠ consensus missing

Bicara Therapeutics Inc. BCAX

Rachel Frank — Vice President

Claire Mazumdar Clemon — Chief Executive Officer

Bill Schelman — Chief Scientific Officer

Ryan Cohlhepp — President and COO

Ivan Hyep — Chief Financial Officer

+1.5%1d on move date+1.3% vs SPY3d−7.0%5d−10.4%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more BCAX calls or request research access.

More BCAX calls Browse calls Request research access